



## WEDNESDAY 8 JUNE

- 16.00h **Opening of the Workshop - Shirley Seo, PhD & Giovanni Di Perri, MD, PhD**
- 16.15h **Opening Lecture: Other Viruses: using Wolbachia to interrupt transmission of viral infections such as Dengue, Chikungunya and Zika**  
**Steven Kern, PhD** - Bill & Melinda Gates Foundation, USA

### Session 1 Pharmacokinetics in infants and young children

**Chairs: Giovanni di Perri & Tim Cressey**

#### Abstract-driven presentations

- |        |  |            |    |
|--------|--|------------|----|
| 16.45h | Pharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women                                     | M. Le      | #1 |
| 17.00h | Raltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection (IMPAACT P1110) | D. Clarke  | #2 |
| 17.15h | Timing of the postpartum curve in pharmacokinetic studies in pregnancy should not be too early                         | A. Colbers | #3 |
| 17.30h | Evaluation of efavirenz and lopinavir concentrations in Plasma and prediction of uptake by nursed infants in Mali.     | A. Oumar   | #4 |
| 17.45h | Discussion   |            |    |

18.00h End of Day 1 - Poster viewing session 1 & Drinks

## THURSDAY 9 JUNE

### Session 2: Hepatitis resistance and pharmacokinetics of DAAs

**Chairs: Shirley Seo & David Burger**

- 08.30h **Role of Resistance Testing**  
**Shyam Kottilil, MBBS, PhD** - Institute of Human Virology, University of Maryland, USA
- 09.00h **The FDA Perspective on Hepatitis C Drug Resistance**  
**Patrick Harrington, PhD** - U.S. Food and Drug Administration, USA

#### Abstract-driven presentations

- |        |   |              |    |
|--------|---|--------------|----|
| 09.30h | Effect of Renal Impairment on Drugs Primarily Eliminated by Metabolism or Biliary Excretion: Review of Data from HCV DAA Drugs and Literature                           | T. Garimella | #5 |
| 09.45h | Effect of daclatasvir/asunaprevir/beclabuvir in fixed-dose combination on the pharmacokinetics of CYP450/transporter substrates in healthy subjects                     | M. Abutarif  | #6 |
| 10.00h | Steady state ribavirin pharmacokinetics in chronic hepatitis C infected patients with moderate renal impairment taking modern DAA combinations: are we dosing too high? | E. Smolders  | #7 |
| 10.15h | Evaluation of Drug-Drug Interaction Between Sofosbuvir/Velpatasvir and Rifaximin in HCV-Infected Subjects with Moderate Hepatic Impairment                              | E. Mogalian  | #8 |

10.30h Coffee break & Poster viewing II - A group picture will be taken directly at the start of the coffee break



## Session 3: Compartmental penetration of Antiretrovirals

**Chairs:** Jonathan Schapiro & Alice Tseng

11.30h	Cumulative tenofovir exposure is associated with decreased BMD in young and old HIV-infected adults on tenofovir based regimens	S. Seifert	#9
11.45h	Intracellular Metabolism of Tenofovir Alafenamide in Cervical and Vaginal Epithelial Cells	M. Cottrell	#10
12.00h	Pharmacogenetics of Efavirenz Discontinuation for Central Nervous System Symptoms at a Southeastern United States Clinic May Differ by Race	P. Leger	#11
12.15h	Virologic and Immunologic Responses to Raltegravir and Dolutegravir in GALT of HIV+ Men and Women	M. Weber	#12

12.30h Lunch

## Session 4: Long Acting Antivirals

**Chairs:** Terry Blaschke & Courtney Fletcher

13.30h	<b>Target Concentrations</b> <b>Angela Kashuba, PharmD</b> - University of North Carolina, Chapel Hill, USA		
14.00h	<b>FDA Perspective on "oral run-in" phase</b> <b>Yodit Belew, MD</b> - U.S. Food and Drug Administration, USA		
14.20h	<b>ViiV - Cabotegravir</b> <b>William Spreen, PharmD</b> - ViiV Healthcare, USA		
14.40h	<b>Janssen - Rilpivirine</b> <b>Herta Crauwels, PhD</b> - Janssen Infectious Diseases, Belgium		
	<b>Abstract-driven Presentations:</b>		
15.00h	Efficacy of once-weekly MK-8591 in SIV infected rhesus macaques	M. Rizk	#13
15.15h	In silico pharmacokinetic/pharmacodynamic simulation of long acting tenofovir injectable formulation for pre exposure prophylaxis strategies.	P. Curley	#14
15.30h	Discussion		

16.00h Coffee Break

## Session 5: Back to the Future: 40 years of Clinical Pharmacology

**Chairs:** Charles Flexner & Giovanni di Perri

16.30h	<b>Looking Backwards: Hormonal Contraception and ART</b> <b>Kimberly Scarsi, PharmD, MS, BCPS-ID</b> - University of Nebraska, USA		
16.50h	<b>Pharmacogenetics - Back to reality</b> <b>Andrew Owen, PhD, FRSB, FBPhS</b> - University of Liverpool, United Kingdom		
17.10h	<b>Will we see the Back of DDIs?</b> <b>Catia Marzolini, PharmD, PhD</b> - University Hospital of Basel, Switzerland		
17.30h	<b>The 'Back Side' of Compartments</b> <b>Saye Khoo, MD, PhD</b> - University of Liverpool, United Kingdom		



- 17.50h **Back-terial co-infections**  
**Mohammed Lamorde, MD, PhD** - Infectious Diseases Institute, Uganda
- 18.10h **Backing up clinical data with modelling**  
**Marco Siccardi, PhD** - University of Liverpool, United Kingdom

18.30h **End of Plenary Program & Workshop dinner**  
 The dinner starts at 19:00h. Please gather in the lobby of the hotel at 18.45h to walk to the restaurant.

## FRIDAY 10 JUNE

### Session 6: Clinical Guidance on how to interpret DDI's

**Chairs: David Back & Jose Moltó**

- 08.30h **Specific Complex Interactions (mechanic presentation)**  
**David Burger, PharmD, PhD** – Radboudumc, Nijmegen, The Netherlands
- 09.00h **Clinical translation of "Amber"**  
**Jonathan Schapiro, MD** – Sheba Medical Center, Israel
- 09.30h **Real life cases**  
**Elise Smolders** – Radboudumc, Nijmegen, The Netherlands

10.00h Coffee break & Poster viewing III

### Session 7: PK/PD of new and existing antivirals: Abstract driven presentations

**Chairs: Shirley Seo & Rodolphe Garraffo**

- |        |  |              |     |
|--------|--|--------------|-----|
| 11.00h | PBPK/PD Modeling and Simulations to Guide Dose Recommendation of Amlodipine after Co-administration with Viekirax or Viekira Pak                                       | D. Mukherjee | #16 |
| 11.15h | Effects of Sofosbuvir/Ribavirin Treatment and ITPA Phenotype on Endogenous Purines   | L. Jimmerson | #17 |
| 11.30h | Rifampin (RIF) Decreases Cabotegravir (CAB) Exposure following Oral Coadministration   | S. Ford      | #18 |
| 11.45h | Increased Tenofovir Diphosphate in Red Blood Cells, but Not Tenofovir in Plasma, with Sofosbuvir and Ribavirin   | C. MacBrayne | #19 |
| 12.00h | MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients | N. Kim       | #15 |
| 12.15h | Discussion   |              |     |

12.30h Lunch



## Session 8: Clinical Pharmacology Updates on New Compounds (by company rep.)

**Chairs: Jennifer Kiser & Angela Kashuba**

13.30h	Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype (GT) 1 and Human Immunodeficiency Virus Type 1 (HIV-1)	J. King	#20
13.45h	Physiologically-based simulation of daclatasvir pharmacokinetics with antiretroviral inducers and inhibitors of cytochrome P450 and drug transporters	T. Garimella	#21
14.00h	A Clinically Meaningful Drug-Drug Interaction Observed Between Zepatier™ (Grazoprevir/Elbasvir) and Stribild® HIV Fixed-Dose Combination in Healthy Subjects	H. Feng	#22
14.15h	Pharmacokinetics of Dolutegravir after Switching to Abacavir/Dolutegravir/Lamivudine from an Efavirenz Based Regimen: A PK Substudy from Striiving	J. Koteff	#23
14.30h	Evaluation of Pan Genotypic HCV NS3/4A Protease Inhibitor GS-9857 as the Object of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions	B. Kirby	#24
	Evaluation of Transporter-Mediated Drug-Drug Interactions with the HCV Combination Regimen Sofosbuvir/Velpatasvir/GS-9857 and Phenotypic Probe Drugs	B. Kirby	#25
14.45h	Discussion		
15.00h	Closure of the workshop		